GBI Biomanufacturing and Allterum Therapeutics have joined forces to manufacture a therapeutic antibody targeting the CD127 receptor for cancer patients.
Collaboration for Breakthrough
The collaboration aims to leverage GBI's expertise in biologics manufacturing to ensure the high-quality production of 4A10, a promising treatment for various cancers.
Excitement in the Industry
Allterum's CEO expressed enthusiasm about moving 4A10 into clinical trials, backed by grant funding specifically allocated for oncology development. The excitement stems from the robust preclinical activity displayed by Allterum's 4A10 across different types of cancers.
FDA Recognition
Additionally, Allterum's 4A10 has received orphan drug designation from the FDA for Acute Lymphoblastic Leukemia (ALL), showcasing its potential as a groundbreaking therapy.
A Milestone in Cancer Research
Successful completion of Phase 1/2a trials for 4A10 would mark a significant milestone in the journey towards developing this anti-cancer drug. The collective efforts of GBI and Allterum highlight a promising future for cancer patients awaiting innovative treatment options in the clinic.